These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7940365)

  • 1. [The functional activity of plasminogen activators in the blood plasma and urine of patients with lupus nephritis].
    Poliantseva LR; Tareeva IE; Bobkova IN; Podorol'skaia LV; Andreenko GV
    Ter Arkh; 1994; 66(6):39-41. PubMed ID: 7940365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The venous occlusion test in assessing the fibrinolytic activity of the vascular endothelium in lupus nephritis patients].
    Bobkova IN; Poliantseva LR; Tareeva IE; Andreenko GV; Podorol'skaia LV
    Ter Arkh; 1995; 67(4):42-5. PubMed ID: 7784974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tissue-type plasminogen activator in patients with lupus nephritis].
    Poliantseva LG; Bobkova IN; Tareeva IE; Podorol'skaia LV; Andreenko GV
    Ter Arkh; 1995; 67(5):17-9. PubMed ID: 7638768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary FOXP3 mRNA in patients with lupus nephritis--relation with disease activity and treatment response.
    Wang G; Lai FM; Tam LS; Li EK; Kwan BC; Chow KM; Li PK; Szeto CC
    Rheumatology (Oxford); 2009 Jul; 48(7):755-60. PubMed ID: 19458162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The criteria for indication of plasma exchange on lupus nephritis].
    Wakai S
    Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):703-13. PubMed ID: 2214318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urinary fibronectin as an indicator of kidney fibrosis in nephritis].
    Kozlovskaia LV; Bobkova IN; Varshavskiĭ VA; Proskurneva EP; Miroshnichenko NG; Chebotareva NV; Mukhin NA
    Ter Arkh; 1999; 71(6):34-8. PubMed ID: 10420453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and morphological characteristics of lupus nephritis in systemic lupus erythematosus with antiphospholipid syndrome].
    Kozlovskaia NL; Shilov EM; Meteleva NA; Varshavskiĭ VA; Miroshnichenko NG; Samokishina NA; Serova AG; Nesterova SG
    Ter Arkh; 2006; 78(5):21-31. PubMed ID: 16889045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator in nephrotic syndrome.
    Andreenko GV; Podoroldskaya LV; Polyantseva LP
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(3):351-5. PubMed ID: 2465229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
    Mak A; Cheung BM; Mok CC; Leung R; Lau CS
    Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical importance of determining the von Willebrand factor in patients with lupus nephritis].
    Bobkova IN; Poliantseva LR; Tareeva IE; Kozlovskaia LV
    Ter Arkh; 1995; 67(5):14-6. PubMed ID: 7638767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of the assays of urinary enzymes activity in patients with systemic lupus erythematosus.
    Delektorskaya L; Janushkevich T; Okunev D
    Z Med Lab Diagn; 1990; 31(7):375-9. PubMed ID: 1982635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis].
    Bumblite ID; Poliantseva LR; Mukhin NA; Andreenko GV; Podorol'skaia LV; Liaginskiĭ AV; Varlamova NV
    Ter Arkh; 1992; 64(11):52-6. PubMed ID: 1293845
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical implication of urine test for markers of endothelial dysfunction and angiogenesis factors in assessment of tubulointerstitial fibrosis in chronic glomerulonephritis].
    Bobkova IN; Kozlovskaia LV; Rameeva AS; Varshavskiĭ VA; Golitsyna EP
    Ter Arkh; 2007; 79(6):10-5. PubMed ID: 17684960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemodynamic mechanisms of lupus nephritis progression].
    Tareeva IE; Shvetsov MIu; Kutyrina IM; Gerasimenko OI
    Ter Arkh; 1998; 70(6):11-4. PubMed ID: 9695215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis.
    Chan RW; Tam LS; Li EK; Lai FM; Chow KM; Lai KB; Li PK; Szeto CC
    Arthritis Rheum; 2003 May; 48(5):1326-31. PubMed ID: 12746905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urine fibrinolytic activity as an indicator of kidney damage in uric acid metabolic imbalance].
    Shcherbak AV; Balkarov IM; Kozlovskaia LV; Podorol'skaia LV; Gindis AA
    Ter Arkh; 2001; 73(6):34-7. PubMed ID: 11521518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
    Shen K; Yu Y; Tang Z; Liu Z; Li L
    Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of monocyte chemoattractant protein-1 and lupus nephritis].
    Liu ZJ; Lin JY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Aug; 27(4):491-5. PubMed ID: 16178446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies in lupus nephritis patients requiring renal transplantation.
    Stinton LM; Barr SG; Tibbles LA; Yilmaz S; Sar A; Benedikttson H; Fritzler MJ
    Lupus; 2007; 16(6):394-400. PubMed ID: 17664229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.